Hou et al. (2020)found that miR-124 was aberrantly expressed in AD and targeting the miR-124/PTPN1signaling was determined as a potential therapeutic strategy of AD. Wu et al. (2020) demonstratedthe increased expression of miR-592 in AD rat model and provided evidence formiR-592 to inhibit neuronal cell viability. Jiet al. (2019) performed a study to investigate therole of miR-22-3p in AD progression, which showed that miR-22-3p overexpressioncould inhibit Aβ deposit by targeting MAPK14. The gene discussed is MAPK14; the disease is Alzheimer disease.